Findings question recommended CVD screening intervals

  • Lindbohm JV & al.
  • Lancet Public Health
  • 1 Apr 2019

  • curated by Dawn O'Shea
  • UK Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

New data from the UK Whitehall II study suggest uniform five-year screening intervals for patients with low and intermediate risk for cardiovascular disease (CVD) leads to unnecessarily long delays in detection of high-risk individuals.

A study, published in the Lancet Public Health, found five-year intervals were unnecessarily frequent for low-risk individuals and insufficiently frequent for intermediate-high-risk individuals.

The study used data from participants in the Whitehall II study (aged 40-64 years at baseline) who had repeated biomedical screenings at five-year intervals and linked these data to electronic health records between baseline (7 August 1991 to 10 May 1993) and 30 June 2015.

Of 6964 participants with 152,700 person-years of follow-up, 1686 progressed to the high-risk category and 617 had a major cardiovascular event.

With the five-year screening intervals, participants spent 7866 person-years unrecognised in the high-risk group. For individuals in the low, intermediate-low and intermediate-high risk categories, 21 alternative risk category-based screening intervals outperformed the five-yearly screening protocol.

The authors say introducing seven-year screening intervals for low-risk patients along with four-year intervals for intermediate-low-risk patients and one-year intervals for intermediate-high-risk would reduce the number of person-years spent unrecognised in the high-risk group by 62 per cent (95% CI, 57-66), while also reducing the number of major cardiovascular events by 8 per cent (95% CI, 7-9 events).

They suggest that screening intervals based on risk-category-specific progression rates would perform better in terms of preventing major CVD events and improving cost-effectiveness.